Colak, R.; Kapar, C.; Degerli, E.; Tacar, S.Y.; Gemici, A.A.; Gergerlioglu, N.; Altinay, S.; Yilmaz, M.
Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy. Medicina 2025, 61, 1168.
https://doi.org/10.3390/medicina61071168
AMA Style
Colak R, Kapar C, Degerli E, Tacar SY, Gemici AA, Gergerlioglu N, Altinay S, Yilmaz M.
Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy. Medicina. 2025; 61(7):1168.
https://doi.org/10.3390/medicina61071168
Chicago/Turabian Style
Colak, Rumeysa, Caner Kapar, Ezgi Degerli, Seher Yildiz Tacar, Aysegul Akdogan Gemici, Nursadan Gergerlioglu, Serdar Altinay, and Mesut Yilmaz.
2025. "Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy" Medicina 61, no. 7: 1168.
https://doi.org/10.3390/medicina61071168
APA Style
Colak, R., Kapar, C., Degerli, E., Tacar, S. Y., Gemici, A. A., Gergerlioglu, N., Altinay, S., & Yilmaz, M.
(2025). Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy. Medicina, 61(7), 1168.
https://doi.org/10.3390/medicina61071168
